# Oculis Holding AG (OCS)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $10.98 (+0.09%)

> Oculis Holding AG is a biopharmaceutical company focused on developing innovative ophthalmic treatments to preserve vision and improve eye care. The company concentrates on diseases with significant unmet medical needs, particularly in retinal and neuro-ophthalmology indications. Its current pipeline includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate targeting dry eye disease; and OCS-05, a disease-modifying candidate being developed for acute optic neuritis and other neuro-ophthalmic disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Operating within the biotechnology segment of the healthcare sector, Oculis Holding AG aims to provide non-invasive or less invasive alternatives to existing eye disease treatments, with an emphasis on topical formulations that may simplify administration for patients and clinicians. Founded in Switzerland and headquartered in Zug, the company plays a specialized role in the global ophthalmology market by addressing complex eye conditions through targeted, research-driven therapeutic programs.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/OCS)